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ABSTRACT
COMPARATIVE MOLECULAR FIELD ANALYSIS (CoMFA)
OF PHENYL RING SUBSTITUTED METHYLPHENIDATES
Comparative Molecular Field Analysis (CoMFA) was performed on 30 methyiphenidate
analogues having phenyl ring substituents at the 2-, 3-, and 4-positions in an attempt to
explain the structure-activity relationships of the analogues. Several CoMFA studies
were carried out using different conformations of methyiphenidate as the template
structures for the corresponding alignment rules. The identification of the bioactive
conformation was variously based on the interfeature distances in WIN 35,428, on cluster
analysis, and on a comparison of active methyiphenidate analogues. The sensitivity of
the models to various CoMFA parameters was compared. These parameters included
altering the size and spacing of the CoMFA grid, and changing different run-time
CoMFA standards such as the steric and electrostatic energy cutoffs, and the column
filtering value. Predictions of "novel", yet-to-be-synthesized methyiphenidate analogues
and of test sets of analogues were carried out using different models. The results showed
that the q2 of a model is affected most by the template structure, followed (in order of
decreasing effect on q2) by the energy cutoffs, the column filtering value, and grid
spacing and region box parameters. It was found that the 2-position analogues have poor
IC50 values because they protrude into a sterically unfavorable region. Based on the
CoMFA studies performed, a novel compound, 3,4-Br methyiphenidate, has been
suggested for synthesis and testing.
COMPARATIVE MOLECULAR FIELD ANALYSIS (CoMFA)
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Cocaine abuse continues to be a major health problem in the United States and has, over
the years, also become a serious threat to a stable society internationally. This study
fauns part of the ongoing attempt to develop a phaiinacotherapeutic agent for the
treatment of cocaine dependence. Such a compound would be a selective dopamine
reuptake inhibitor in that it would exhibit a high binding affinity for the dopamine
transporter and simultaneously permit some magnitude of dopamine reuptake. One class
of compounds which exhibits these characteristics is the methyiphenidate analogues. The
mechanism of action of methyiphenidate (Ritalin ®) is similar to that of cocaine. 1-4
Studies of methyiphenidate analogues have shown that some threo-methylphenidate
derivatives with halogen substituents on the aromatic ring have increased binding
affinity. 1,5-10 Furthermore, for most aromatic ring substituted compounds there was a
clear correlation between their binding affinity and their ability to substitute for cocaine
in drug discrimination studies. However, as the three-dimensional structure of the
cocaine receptor site is unknown, the design of new ligands must be based on structure-
activity relationships derived from a set of known ligands. Comparative Molecular Field
Analysis (CoMFA) is at present the most widely used approach for three-dimensional
quantitative structure-activity relationship (3D-QSAR) studies.
The objective of this research is twofold. First, to use CoMFA to elucidate
structure-activity relationships of methyiphenidate analogues with phenyl ring
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substituents. Second, to use CoMFA to predict the activity of novel methyiphenidate
analogues. This research is one component of the iterative cycle of concerted drug
development using molecular modeling, synthesis, binding and behavioral studies. Thus,
molecular modelers use available experimental data to propose a novel compound that is
synthesized and then tested for biological activity. The feedback obtained from testing is
used to fine-tune the predictive model and the cycle is repeated until a satisfactory
compound is realized. The methyiphenidate analogues examined in this study were
synthesized in the laboratory of Dr. Howard Deutsch at Georgia Institute of Technology,
while testing was carried out in the laboratory of Dr. Margaret Schweri at Mercer
University School of Medicine. This work was supported in part by NIH grant
DA11541. By determining exploratory CoMFA models using phenyl ring substituted
methyiphenidate analogues, this research marks a beginning in molecular modeling
studies on methyiphenidate analogues in particular and on dopamine reuptake inhibitors
in general.
1.2 Outline
The remainder of Chapter 1 presents the rationale of this research including a discussion
of the hypothesized mechanism of cocaine action, the importance of the dopamine
transporter and the "Dopamine Hypothesis", and the significance of methyiphenidate
analogues. Chapter 2 introduces the development of CoMFA as a powerful predictive
tool, and describes its important components such as the statistical Partial Least Squares
technique and the Leave-One-Out cross-validation. Conformational analysis, the
selection of a template structure (for alignment) that could reflect the bioactivity of the
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methyiphenidate analogues, and the generation of a suitable molecular alignment of the
30 analogues considered in this study form important steps in the preparation for actual
CoMFA experiments and are considered in Chapter 3. Several CoMFA experiments
were carried out, using different alignments, to compare the sensitivity of the results to
variations in the CoMFA parameters used. Some of these studies included altering the
size and spacing of the CoMFA grid, changing different run-time CoMFA parameters,
and prediction of "novel" compounds and of "test set" compounds. Chapter 4 illustrates
results obtained from these experiments. Finally, Chapter 5 discusses the conclusions.
1.3 Background
1.3.1 About Cocaine
An alkaloid extracted from the leaves of the coca plant, cocaine is a powerful local
anesthetic with vasoconstrictor properties. It is also used and abused as a mental
stimulant that is capable of generating a series of epinephrine-like reactions due to the
stimulation of the sympathetic nervous system and release of epinephrine. The desired
effects of cocaine are feelings of euphoria, alertness, excitement, and rapid flow of
thought but these could be expressed as hyperactivity, increased confidence,
talkativeness, and mood-shifts. As a stimulant, it helps to combat fatigue and instill
feelings of increased capacity to do work, great physical strength, and mental superiority.
In the brain, cocaine inhibits reuptake of dopamine (DA), norepinephrine, and
serotonin in central and peripheral nerve synapses' 1-15 and thus effectively prolongs and
augments their effects. The inhibition of dopamine reuptake is thought to cause euphoria
and is the main reason why users continue to take the drug. Mice that have been
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genetically altered to lack a central dopamine reuptake mechanism at synapses do not
respond to cocaine at al1. 16
1.3.2 The Dopamine Transporter
The dopamine transporter (DAT) is thought to contain a specific binding site for
cocaine. 17 Dopamine nerve endings have unique, high-affinity dopamine uptake sites
that play a key role in terminating transmitter action and in maintaining transmitter
homeostasis. A membrane carrier that is capable of bi-directional transmission of
dopamine is responsible for uptake. 18 The dopamine transporter recycles dopamine in the
synaptic cleft by recycling extracellular dopamine (ECDA) back into the nerve terminal.
The structural and pharmacological features of the dopamine transporter have been
reviewed, 19 and rat,20-22 bovine,23 and human24 dopamine transporters have been cloned
and characterized. The human DAT is 92% identical to the rat DAT and 84% identical to
the bovine DAT. The human DAT is a protein made of 620 amino acids and has three
glycosylation sites. It is hypothesized to contain 12 hydrophobic putative
transmembranal domains and is a member of the family of Na±/C1" -dependent plasma
membrane transporters. Chimeric dopamine-norepinephrine transporters have been
employed to describe distinct domains for ionic dependence and uptake mechanisms
(domains 1-5), cocaine and tricyclic antidepressant interactions (domains 6-8), and
substrate affinity and stereoselectivity (domains 9-12) on the DAT. 25 In the seventh
transmembrane segment, there are several closely spaced serine residues that could act to
bind the hydroxyl groups of DA. Kitayama, et al. 26 have shown that replacement of some
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of these serine residues by glycine or alanine in the rat DAT completely impairs DA
uptake ability.
1.3.3 The "Dopamine Hypothesis"
According to the "Dopamine Hypothesis", 27 the reinforcing properties of cocaine arise
when cocaine binds to the dopamine site on the DAT inhibiting the reuptake of DA by
the DAT. This raises the ECDA levels and eventually leads to euphoric and addictive
effects.28 The finding that binding of cocaine in some of the chimeric dopamine-
norepinephrine transporters can be virtually eliminated without affecting the uptake
properties suggests that a specific determinant for cocaine binding must exist
independently of the binding of substrate. This implies that an antagonist of cocaine
action without uptake blockade activity could be developed for clinical use for
controlling drug dependence. Such a compound would bind to some part of the cocaine
site on the DAT but would not inhibit DA reuptake. The drawback of this approach is
that the patient could annul the effect of treatment simply by self-administering more
cocaine, leading perhaps to dangerous side effects such as cardiac arrhythmias.
Rothman, et al.29,3° suggest a different strategy by seeking to develop a DAT-selective
drug that binds with high affinity to, but dissociates slowly from, the DAT, such that it
behaves like a noncompetitive inhibitor to cocaine. By partially inhibiting DA reuptake,
the ideal agent would provide sufficient ECDA to minimize cocaine craving, yet
insufficient to produce euphoria. The ideal agent would also be insoluble in aqueous
solution to preempt patients from covertly self-administering it intravenously.
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Pharmacologically, a number of drugs have been used to reduce cocaine use,
decrease craving, and alleviate dependence or symptoms of withdrawal. Research has
concentrated mainly on two approaches. In the first, antidepressants 31,32 have been used
because cocaine abstinence produces symptoms similar to depression but these invariably
produce troublesome side effects. 33,34 The second popular approach has been to employ
drugs that interact with DA because of this neurotransmitter's important role in the
positive reinforcement produced by cocaine. Drug development targeting the DAT has
resulted in the generation of some very potent and selective molecules of diverse
structural backgrounds. 35-37 The identification of radioligands, such as nomifensine, 38
methylphenidate,39 1[2-(diphenylmethoxy)-ethyl]-4-(3-phenylpropy1)-piperazine (GBR
12935)540,41 mazindo1, 12 N-[1-(2-benzo(b)thiophenyl)cyclohexyli pipericline (BTCP), 42
benztropinel 1,37,43 and its analogues, 37,44-50 and cocaine and its analogues 17,38-42,51-58 which
bind to the DAT and influence the reuptake of DA has led to a wealth of structure-
activity data, much of which has been summarized recently. 35,59-63 To date, a selective
dopamine uptake inhibitor with the characteristics of the ideal agent outlined above has
not been identified.
1.3.4 The Pharmacophore Model
According to Kier 64 who popularized the term in the late 1960s, a pharmacophore
consists of those structural features that impart to a molecule a particular pharmacological
activity. A pharmacophore model for the ideal agent defines the three-dimensional
geometric arrangement between chemical moieties (such as a carbonyl group or aromatic
ring) or chemical features (such as a hydrogen bond donor or acceptor) that have been
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identified from the experimental structure-activity data as being required for biological
activity. As additional structure-activity data becomes available, the pharmacophore
model for a particular set of molecules can be refined further. The available structure-
activity data for methyiphenidate analogues are discussed below.
1.3.5 Structure-Activity Relationships (SAR) of Methyiphenidate Analogues
Methyiphenidate (MP) is a central nervous system stimulant that is the drug of choice for
the treatment of Attention Deficit Hyperactivity Disorder in children. It was first
synthesized over 50 years ago 65 and was recognized as a stimulant ten years later. 66
Recently, because of the similarity of its mechanism of action to that of cocaine, 1-4 there
have been several studies of MP analogues. 1,5-10 All of the structure-activity studies to
date originate from the laboratories of Drs. Howard Deutsch and Margaret Schweri 67-72
and have been recently reviewed. 61 The data presented here come from these studies
(both published and unpublished) and reflect the analogues' ability to inhibit the binding
of [ 3H]WIN 35,428 to rat striatal tissue membrane preparations, as well as the uptake of
[ 3H]dopamine into rat striatal synaptasomes. 67 The studies indicate that some threo-MP
derivatives with halogen substituents on the aromatic ring have increased binding affinity
compared to the unsubstituted threo-MP. Electron-donating substituents caused little
change or a small loss of affinity. N-substituents generally caused a marked loss of
affinity, except for the benzyl moiety that has slightly increased affinity. For the
unsubstituted amine, reduction of the methyl ester to a hydroxyl sharply reduces affinity,
whereas conversion of the hydroxyl to a methyl ether restores affinity. For N-benzyl
(tertiary amine) derivatives, the same changes increase affinity. Although the activity of
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the MP derivatives was highly correlated in the binding and uptake assays, 67 a number of
compounds were 4- to 8-fold more effective at inhibiting [ 3H]WIN 35,428 binding than
[3 H]dopamine uptake. For most aromatic ring substituted compounds, there was a clear
correlation between their binding affinity and their ability to substitute for cocaine in
drug discrimination studies. This correlation did not hold for N-substituted analogues
which were generally much less potent in the drug discrimination test than predicted by
their binding affinity. A pharmacophore model has been proposed to explain the similar
pharmacological properties of cocaine, MP, and the WIN analogue CFT. 73 This model
identifies the protonated amine, the ester group, and the aromatic ring as important
structural elements. Superposition of the sequence of atoms from the amine group
through the ester group of the (+)-(R, R)-threo-MP (calculated from the X-ray structure),
CFT, and cocaine showed the similarity of these positions in space, with the phenyl rings
of the three compounds oriented in very different regions of space. Froimowitz and
coworkers73 concluded that the DAT can accommodate a wide variety of positions of the
phenyl ring. However, it is possible that the DAT site, which accommodates the C-2
position substituent, is a large lipophilic pocket, or that the DAT site may accommodate
all three phenyl rings in the same orientation, thereby forcing the 2-position substituents
into different parts of the lipophilic pocket. The authors did not propose a detailed
pharmacophore model for MP nor did they investigate superposition of other low energy
conformers of the ligands or alternative superpositions, or attempt to explain the
structure-activity relationships of the MP analogues. It is here that molecular modeling
studies incorporating CoMFA of the MP analogues may be useful. The research
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presented here is an attempt to generate CoMFA models based on an analysis of the
structure-activity relationships of MP analogues with phenyl ring substituents.
The published61,67 and unpublished binding and uptake data for the 30 MP
analogues indicate that the more active compounds, defined as those with the higher
affinity for the binding site (lower IC5 0), are 3- or 4- substituted, such as for example, 3-
Br (binding IC 50 = 4.2 nM), 3-Cl (5.1 nM), 3,4-C1 (5.3 nM), and 4-Br (6.9 nM). The
unsubstituted MP analogue has a binding IC5 0 value of 83.0 nM and an uptake IC 5 0 value
of 224.0 nM. In general, 3- and 4- substituted compounds have comparable IC 50 values
while the 2-substituted compounds are relatively much less active, having much higher
IC50 values. This is probably because of increased steric effects introduced in the
compound by the 2-position substituent. The use of CoMFA may help establish such a




Comparative Molecular Field Analysis (CoMFA) is one of the most powerful tools in the
area of three-dimensional quantitative structure activity relationships (3D-QSAR) studies.
It was developed by Cramer, et al. 74 for predicting the biological activity of a drug and is
based on the assumption that the interactions between the ligand and its receptor site are
primarily non-covalent in nature. Since most drugs exhibit biological activity first by
binding to a target receptor molecule, CoMFA assumes that changes in the biological
activities of drug molecules correspond to changes in their steric and electrostatic
energies, which, in turn, are considered to be the chief components of drug-receptor
interactions. The method itself contains six fundamental steps: (1) selection of a
bioactive conformation of each compound under study; (2) superposition of selected
structures in an alignment that best approximates the putative alignment of the active
drugs at the receptor site; (3) generation of grid points with regular spacing around the
molecules under investigation; (4) sampling of the steric and electrostatic interaction
between the investigated molecule and the probe atoms at each grid point; (5)
construction of the model equation between the interaction energies and biological
activities of the molecules in the series using Partial Least Squares (PLS) analysis; and
(6) display of the coefficient contour maps of the PLS model equation by computer
graphics. Of these six steps, the first two (i.e. the selection of a suitable template
structure and the subsequent alignment rule) are described for MP analogues in Chapter
10
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3. The remaining four steps are incorporated into the CoMFA Studies described in
Chapter 4.
The CoMFA technique has been successfully used for the prediction of the
biological activity of many different types of drugs, such as cocaine analogues, 75-77
benzodiezapine inverse agonists, 78 drugs that act at the cannabinoid receptor,79
anticoccidial triazines, 80 drugs that bind to the human rhinovirus, thermolysin, and
renin, 8 i 5-HT5A receptor agents, 82 imidazoline receptor ligands, 83 N-methyl-D-protease
inhibitors, 84 phenothiazines and other multidrug resistance modifiers, 85 dopamine
receptor agonists, 86 and HIV-1 protease inhibitors. 87 About 400 CoMFA papers were
published during 1993-1997 alone. 88 Recent reviews of the methodology have pointed
out its scope and limitations. 89-92
Since the molecular structure and properties of the cocaine receptor site are
unknown, CoMFA is perfouned by calculating and comparing the molecular steric
(Lennard Jones) and electrostatic (Coulombic) "fields" of both active and inactive
analogues. These fields are calculated at each lattice point around each analogue using a
probe atom, such as a sp a carbon atom with +1 charge, at regularly-spaced points on the
three-dimensional CoMFA grid. The energy values thus calculated are entered into
columns in a CoMFA QSAR table. Application of special multivariate statistical
analyses routines, such as Partial Least Squares analysis, cross-validation, and
bootstrapping, produces a statistically significant final CoMFA equation. The result of
this analysis is a "cross-validated r2" (called q2), which is a quantitative indication of the
quality of the final CoMFA model. A q2 value close to 1.0 suggests that the model
equation is most predictive, and when it is small or negative, the model equation is not
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good enough for prediction. A q2 value of greater than 0.5 is considered significant. The
optimum number of components generated by the cross-validated analysis (see Sections
2.2 and 2.3) is used to perform a non-validated analysis. The results of this non-validated
run are displayed as three-dimensional color-coded contour plots that show differences in
the steric and electrostatic fields and, therefore, illustrate the differences in binding
affinity due to particular substituents. These maps help the user to easily identify the
properties in particular regions of space that correspond to increased biological activity
and vice-versa. It should be kept in mind, however, that the accuracy of the
pharmacophore model in predicting activity of new compounds depends on the quality
and availability of experimental structure-activity data.
The two biggest hurdles in generating a CoMFA model with a diverse set of
molecules are the selection of the bioactive conformation and the need for a suitable
superposition rule. Often these two procedures are subjective and time-consuming, and
could compound the problem by being interdependent. For most studies, superposition
so that the most important pharmacophore features (such as hydrogen bond donors and
acceptors, aromatic rings, and hydrophobic regions) are aligned is sufficient for good
results. 90 This is a straightforward procedure in the case of structurally-related analogues,
such as the methyiphenidate analogues considered here. It may be more difficult to
define the important pharmacophore features (and thereby the superposition rule) for
comparison of molecules from several different structural classes. Most studies seem to
choose the global energy minimum gas phase conformation as the bioactive
conformation76,77,93 , even though there is evidence from ligand-protein binding studies
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that the bound conformation of the substrate is different (sometimes dramatically so)
from the gas phase global energy minimum conformation.94 '95
2.2 Partial Least Squares Technique
Partial Least Squares (PLS) is a popular regression method developed by H. Wold and S.
Wold and is used to solve the multivariate structure-activity relationships in QSAR
studies. 96 The three-dimensional information that is obtained from calculating the steric
and electrostatic field energy values (i.e. descriptors) at each point on the CoMFA grid is
placed in a two-dimensional CoMFA QSAR table. This table contains hundreds or
thousands of such descriptors for each molecule. PLS assumes that these descriptors
capture the dominant effects due to changes in molecular substructure. Depending on the
probe used in the molecular calculations, these descriptors may be electrostatic and steric
energy values (as mentioned above) or lipophilic or other contributions to the ligand-
receptor interaction. PLS also assumes the presence of a small number of "intrinsic"
variables (called latent variables) that contain all the information relevant to the
biological activity. The result of a PLS analysis is an equation that describes or predicts
the differences in the values of one or more table columns (the dependent variables, or
target properties, such as the biological activity given by the IC50 value) from differences
in the values in other table columns (the descriptors).
In PLS, the relationship between the parameters of the given samples (X) and the
corresponding responses (y) is described using a linear model equation with latent
variable t. The latent variable t is expressed by the linear combination of parameters
(equation I).
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t = Xw 	 (1)
where w is the weight factor for calculation of the latent variable. Bilinear model
equations are shown in equations 2 and 3.
X= 	 tipi + E 	 (2)
fr-1
A
Y	 uiqi + F	 (3)
where: u = latent variable for the response variable
p loadings corresponding to t
q loadings corresponding to u
E = model residuals for X
= model residuals for Y
A = number of components in the PLS model equation
2.3 Leave-One-Out Cross-Validation
The number of PLS components (A) is usually determined by means of the Leave-One-
Out cross-validation method. In this procedure, the data for one of the ligands is deleted
and a CoMFA model is constructed and used to predict the biological activity of the
deleted ligand. The predicted error sum of squares (PRESS), the cross-validated
correlation coefficient (q2), and the cross-validated standard error of estimate (scy) are
computed as shown in equations 4-7. The data for that ligand is then restored to the set
and the data for the next ligand is deleted. The CoMFA model is derived again and used
to predict the activity of the second ligand and so on for each ligand in the set.
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where: Y	 = set of all samples
Ypred = a predicted value
Yactual	 an actual or experimental value
Ymean = the best estimate of the mean of all values that might be predicted
n	 = number of rows
A	 = number of components
SS	 = sum of squared residuals (actual)
sc,	 = cross-validated standard error of estimate
The number of components to be used in the non-validated run (i.e. the optimum number
of components) is selected as the number of components that significantly reduces s cv (or
increases q2), or that corresponds to the minimum scv (or to the maximum q2). After the
non-validated run, the resulting CoMFA model is then used to predict the activity of a
new molecule. It should be noted, however, that the new molecule cannot differ too
much from those used to derive the CoMFA equations; usually, the difference is
restricted to a small region of the molecule such as a substituent. This new molecule is
added to the set, superimposed on the template, and its steric and electrostatic fields are
calculated. The results are displayed as three-dimensional contour plots that correlate
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steric and electrostatic features in particular regions of space with increased or decreased
bioactivity. Finally, the predicted r 2 and s„ values are calculated to get a quantitative
idea of the bioactivity of the new molecule.
CHAPTER 3
CoMFA METHODS
3.1 Software and Hardware
The conformational analysis and the CoMFA studies described here were carried out
using SYBYL (version 6.5), a pharmacophore modeling package available from Tripos,
Inc. Calculations were carried out on a Silicon Graphics 02 workstation (4.2 GB hard
drive, 128 MB RAM) at New Jersey Institute of Technology.
3.2 Conformational Analysis
This study investigated 30 neutral MP analogues with aromatic ring substitution at the 2-,
3-, or 4-position as shown in Figure 3.1. Methylphenidate has two asymmetric carbon
atoms (Cl and C2 in Figure 3.1) and can therefore exist as two pairs of diastereomeric
enantiomers. Most pharmacological activities of MP seem to be associated with the threo
isomer whose (+)-enantiomer is believed to be responsible for the stimulant
properties. 6,68,97-102 The absolute configuration of this active enantiomer has been
determined to be (R,R). 103 It was thus decided to use for this study the threo analogues
having the (R,R) absolute configuration.
Figure 3.1 The Methyiphenidate Analogues Investigated in This Study
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Investigation of the conformational space of a molecule is inherently a difficult
process 104-106 but is necessary for many computer-aided analyses such as CoMFA.
Methyiphenidate is a flexible molecule as it contains readily rotatable single bonds, and is
structurally somewhat similar to cocaine, which is shown in Figure 3.2. Conformational
analysis to search the conformational potential energy surface of the MP analogues and to
generate a set of low-energy conformers for use in the pharmacophore model was
performed using the RANDOMSEARCH utility and the SYBYL Maximin2 force field. A
cutoff value of 5 kcal/mol above the global energy minimum (GEM) was used to choose
the conformers to be considered for analysis. Four torsional angles affecting the relative
orientation of putative pharmacophoric elements (i.e. the nitrogen, the ester group, and
the phenyl ring) were selected to be randomly altered. The four bonds involved were the
three between the central carbon atom and the phenyl ring, the piperidine ring, and the
carbomethoxy side chain, and that between the carbonyl carbon and methoxy oxygen.
These are indicated for unsubstituted MP in Figure 3.3.
procedure. RANDOMSEARCH randomly alters the selected torsional angles to find the
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various energy minima available to a given molecule and minimizes the energy of the
resulting geometry. After minimization, the conformation is compared with those
already located and is saved if it is unique. The RMS superposition threshold value (0.2
A here) defined during RANDOMSEARCH setup distinguishes between two minima: a RMS
value greater than the threshold represents two different conformations. Minimization
was carried out using the Powell method with a maximum number of 1,000 iterations
allowed. The Gasteiger-Hiickel method of charge computation was used during
minimization. This method combines the Gasteiger-Marsili method (to calculate the a
component of the atomic charge) and the Hiickel method (to calculate the rc component of
the atomic charge). 107-111 The total charge is the sum of the charges computed by the two
methods. A distance-dependent dielectric function was used with dielectric constant of
1.0. A cutoff of 8 A was set on the non-bonded interactions. To ensure a comprehensive
search of 3D space, the RANDOMSEARCH routine visited 10,000 conformations of each
analogue and took 2-3 days per analogue to run on the workstation. During random
searching, the (R,R) configuration of the threo analogues was preserved (see Appendix
B) as was the low-energy chair conformation of the piperidine ring. In trial
RANDOMSEARCH runs, it was found that the piperidine ring tended to undergo "ring
inversion", changing the bulky substituent (i.e. the carbon atom attached to the phenyl
ring and to the ester group) from the equatorial position to axial. Since the equatorial
position is known to be more stable (assuming the absence of other interactions such as
hydrogen bonding that could stabilize an axial conformation), the piperidine ring was
held rigid in the chair conformation during the random search. For the same reason, the
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hydrogen atom on the nitrogen was also retained in its equatorial position during random
searching.
Table 3.1 Conformational Analysis of Methyiphenidate Analogues
a) Within 5 kcal above GEM. b) For CoMFA study 1. c) "State" refers to the relationship of the conformer selected for superposition
to the GEM of analogue. d) Energy of selected conformer relative to GEM of analogue.
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Table 3.1 lists the number of unique conformers (as defined from the RMS
superposition threshold of 0.2 A) found by RANDOMSEARCH for each analogue. The table
shows that random search of the MP analogues produced a low of 19 conformations (for
the 4-Br analogue) and a high of 113 conformations (for the 3-OCH3 analogue) within
just 5 kcal/mol of their respective global energy minima. The large number of
conformations found for the methoxy-substituted analogues are due to rotation of the
methyl group. To get a good predictive CoMFA model, it is necessary to choose for
alignment conformers that are representative of the bioactivity of the MP analogues, as
discussed in the next section.
3.3 Selection of Bioactive Conformer
Most compounds of biological importance are usually large enough to possess several
rotatable bonds that allow the compound to exist in several different low-energy
conformations. For example, the most active conformer of a certain analogue may not be
the gas-phase global energy minimum, which could be an intuitive first choice and was
used by several researchers. 76,77,93 Others have used a higher-energy conformation, up to
12 kcal/mol above the GEM conformation, as the bioactive conformation. 112 However, it
should be noted that there may be several reasons for selecting conformers not based on
Boltzmann distribution and conformational energies. In this context, according to
Yliniemela et al., 113 first, the molecular mechanical or semi-empirical conformational
energies may not be very accurate. Second, the selected low-energy conformer may not
properly reflect solvent and physiological effects. Third, if its energy is not too high
above the GEM, even a non-optimal conformer may have a significant presence. Recent
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CoMFA investigators, such as Debnath, 87 have used their knowledge of molecular
structure and properties of receptor sites in identifying suitable conformers of their ligand
analogues. Using this knowledge, they were able to restrict their choice of conformers to
only those that could possibly bind with the receptor. However, in the absence of
knowledge of the receptor site structure, as is the case here, the problem is more difficult.
3.3.1 Identification of Bioactive Conformer Common Only to Active Analogues
In general for the MP analogues, when all the conformers generated for a particular
analogue were superimposed using the piperidine ring and the central chiral carbon atom,
roughly three different "classes" of phenyl ring orientation in space were identified. This
is shown for MP in Figures 3.4 and 3.5.
Figure 3.4 Superposition of RANDOMSEARCH Conformers of Methyiphenidate
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Figure 3.5 The Same Superposition Rotated to Show the Near-Perfect Alignment of
Piperidine Rings of the Conformers
Theoretically, if the bioactive conformer for MP were within 5 kcal/mol of MP's
GEM conformation, it would fall into one of the three classes shown in Figure 3.4. If this
conformer could be identified, it could be used as a template for the alignment necessary
for CoMFA of the 30 analogues. The assumption was made that the 2-position analogues
are relatively inactive (with high IC50 values) because they cannot easily attain the
bioactive conformation, whereas the 3- and 4-position analogues are active because they
can easily attain the bioactive conformer (i.e. that the bioactive conformer would be
found among the local minima located by RANDOMSEARCH). Therefore, an analysis of
the four randomly-altered torsional angles was carried out for all conformations of MP
and the 2-, 3-, and 4-substituted Br, Cl, F, OCH3, and OH analogues in Table 3.1. For
each analogue, scatter graphs (see Appendix C) of 1:1)1 vs. 02, 1)1 vs. 03, and 02 vs. 03
were created (see Figure 3.3 for torsion angle definitions). The aim was to establish
whether there was a region or point in torsion space (i.e. within 5 kcal/mol of each
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analogue's GEM conformation) that was accessible to those analogues with low IC50
values (i.e. MP and the 3- and 4-analogues) but not to those analogues with high IC 50
values (i.e. the 2-analogues). The search for the presence in the scatter graphs of MP and
the 3- and 4-analogues and absence in those of the 2-analogues of a conformer/point was
initially based on the reasoning that the 2-substituent may have poorer steric interactions
with the rest of the molecule costing it more than 5 kcal/mol to attain the bioactive
conformation. As such, it was useful to look first at the (1)2 vs. 03 scatter plots for the
analogues since this would pit the 2-substituent against the carbonyl oxygen (for greater
steric hindrance). As expected from the size and location of the substituent, the 2-
analogues appear to have a much more conforrnationally restricted torsional angle space.
From all three sets of graphs, however, no conformation was identifiable that was
common to MP and all 3- and 4-substituents but not to the 2-analogues.
Since this result could stem from the possibility that the bioactive conformer
might not fall within the 5 kcal/mol energy cutoff, the 30 analogues were subjected to
RANDOMSEARCH again using a higher 20 kcal/mol energy cutoff value. This time the new
sets of conformations for MP and all the 2-position analogues (Br, Cl, F, OCH 3 , and OH)
were plotted in 3D with 4)4, 4)2, and 03 as the three axes. First, all the local minima for
MP within 20 kcal/mol of its GEM conformation were plotted in green. Then all the
local minima for all the 2-position analogues (within 20 kcal/mol of their respective
GEM conformations) were plotted in red. The two plots were superimposed to produce
the figure shown in Plate 1 in Appendix D. The actual value of the energy of each
conformer is not important here; rather just the fact that each point identifies a local
minimum with the 20 kcal/mol cutoff. An attempt was made to locate a green point that
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had no red neighbors in 3D torsional angle space. Such a point could signify a bioactive
conformation that is allowed for MP but not for the 2-analogues and could be used as a
template for alignment of the 30 analogues for CoMFA. Seven such points were
identified: MP conformation numbers 27 (energy = 12.72 kcal/mol), 39 (18.85 kcal/mol),
40 (19.82 kcal/mol), 42 (12.19 kcal/mol), 45 (19.95 kcal/mol), 59 (7.5 kcal/mol), and 65
(12.67 kcaUmol). If the 3- and 4-position analogues are active, one would expect them to
have the same bioactive conformation as MP. The scatter plots for selected 3- and 4-
analogues were investigated to see whether a conformation could be found that was
common to MP and 3- and 4-position analogues but not found for the 2-position
analogues. The results, as shown in Table 3.2, convey that no consistent pattern
emerged.
Table 3.2 Trial Bioactive Conformations of MP Analogues
1 — yQb, auctivE,u, has 	1A)11illiilbaLISJ11, 1•1 — LIU
3.3.2 Identification of Bioactive Conformer Based on Interfeature Distances in WIN
35,428
As a next step, it was felt that the bioactive conformer of the MP analogues might be
defined from that of the highly active cocaine analogue WIN 35,428 used by Schweri and
coworkers to radio-label the cocaine binding site. Subsequently, RANDOMSEARCH was
performed on WIN (Figure 3.6) and conformers within 20 kcal/mol of the GEM of WIN
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were investigated. The distances between the nitrogen and the aromatic centroid
(represented by the 2- or 5-position hydrogen, Hi and H2 respectively), the nitrogen and
the two oxygens (01: carbonyl oxygen and 02: methoxy oxygen), and the oxygens and
the centroid were calculated for each of the WIN conformers. These distances along with
the energy values of the 16 RANDOMSEARCH WIN conformers are given in Table 3.3,
with the WIN GEM conformation (number 4) listed in bold. The distance calculation
was repeated for MP and some of the 3- and 4-analogues and the distances and energies
found for the 67 RANDOMSEARCH MP confofiners are given in Table 3.4, with the MP
GEM confotination (number 14) values listed in bold. The idea was to see if any
conformer of MP, 3-, and 4-analogues had the same distances between relevant features
as one or more conformers of WIN since this conformer might be bioactive (and
therefore suitable to use for CoMFA alignment). This method of identifying the
bioactive conformer for MP analogues was also not successful, primarily because of the
different size of the MP analogues and WIN, with the MP analogues being much
"shorter" than WIN in all the inter-feature distances.
Figure 3.6 WIN
Table 3.3 Energy and Interfeature Distances for WIN Conformers
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Table 3.4 Energy and Interfeature Distances for MP Conformers
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3.3.3 Identification of Bioactive Conformer by Cluster Analysis
An alternative definition of the different classes of the MP conformers was attempted by
using hierarchical cluster analysis on the MP conformers obtained by RANDOMSEARCH.
Hierarchical cluster analysis is a means to locate various groupings that might be present
in a given data set. It can be used to see which structures are most similar in terms of the
selected distance metric, as well as to choose a compound or a subset of compounds that
could be considered representatives of the larger data set. The cluster analysis results are
displayed as an inverted tree, or a dendrogram. Based on the selected criterion for
clustering (such as torsional angles, distances between atoms or features, etc.), the
analysis moves from the bottom of the dendrogram to the top, progressively merging
pairs of clusters. Each node at the bottom represents a row (or conformer), while the top-
most cluster represents the entire table (such as the molecular spreadsheet containing the
different RANDOMSEARCH conformers of an analogue). The lengths of the vertical lines
in the dendrogram provide qualitative information about the separation between various
clusters with a shorter branch signifying greater similarity between the clusters. Clusters
represented by long unbranched strands are strongly separated from other clusters. A
dendrogram that has well-formed clusters has most of the original nodes merging at its
bottom.
The cluster analysis was done on the 67 MP conformers generated by using the
energy cutoff value of 20 kcal/mol during RANDOM SEARCH. The four torsional angles 01,
02, 03, and 04 shown in Figure 3.3 were chosen as the criterion for clustering. The
resulting dendrogram is illustrated in Figure 3.7 and the torsional angles in Table 3.5.
One way to select subsets is to select all points at a particular vertical level and then
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choose one member from each resulting group. Accordingly, five points were chosen
near the top of the dendrogram in order to divide the 67 MP conformations into five
families, as shown in Figure 3.7. The lowest energy structure from each of the five
families was then selected as a potential bioactive conformer with which five different
CoMFA experiments could be carried out. The conformer chosen from the first family
was conformer number 1 (with energy = 7.00 kcal/mol), from the second was conformer
number 3 (5.33 kcal/mol), from the third was conformer number 14 (0.54 kcal/mol), from
the fourth was conformer number 17 (1.31 kcal/mol), and from the fifth was conformer
number 20 (5.43 kcal/mol). Of these, conformer number 14 was the GEM structure for
the 67 MP conformations. This structure (energy = 0.54 kcal/mol, = 175.6, 02 = 74.1,
= 3.6, 04 = 179.3) was very similar to the GEM structure (energy = 0.53 kcal/mol, 1
= 177.1, 02 = 74.6, 03 = 3.2, 04 = 178.9) of the 20 MP conformers obtained earlier using
the 5 kcal/mol RANDOMSEARCH energy cutoff value. By the time cluster analysis was
performed on the 20 kcal/mol RANDOMSEARCH MP conformers, CoMFA Study I had
already been carried out using the 5 kcal/mol MP GEM structure as the template for
alignment (which is described in the next section). Given the similarity between the two
MP GEM structures, it was decided to leave out conformer number 14 from the CoMFA
studies. In all, five CoMFA studies (using the 5 kcal/mol cutoff GEM conformer, and
conformer numbers 1, 3, 17, and 20 from the 20 kcal/mol cutoff data set) were done and
are described in the next chapter.
Figure 3.7 Dendrogram for MP Conformers (20 kcal/mol Cutoff)
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Molecular alignment plays an essential role in areas such as 3D-QSAR, pharmacophore
identification, molecular diversity, and structural database searching. 114,115 The results of
CoMFA also are strongly dependent on the alignment of the analogues. 74 The structures
for the first CoMFA study were aligned by first choosing the GEM structure of
unsubstituted MP (from the 5 kcal/mol data set) as the template and then superimposing
the GEM structure of each analogue on the template by superimposing the six aromatic
carbons and the piperidine nitrogen. The alignment was carried out in SYBYL using its
"Align Database" option, which superimposes the structures by minimizing the RMS
distance between each aligned analogue and the template structure (see Appendix B). As
shown in Figure 3.8, this superposition produced an alignment in which the piperidine
ring, the ester side chain, and the phenyl ring overlap almost exactly for all analogues
except 2-OH, 3-NH2 , and 4-NH2. In addition, in this alignment, the 2-position
substituents on the phenyl ring lie on the opposite side of the 3-position substituents,
essentially turning the 3-position substituents into 5-position substituents relative to the
2-position substituents. For a coherent analysis, it was decided to have, as a requirement
for the alignment for CoMFA, all analogues with substituents on the same side as the 2-
position analogues. Table 3.1 lists for each analogue the conformer number selected for
the new alignment and also its relationship to the GEM structure of the analogue. For
example, for the unsubstituted MP analogue, 20 conformers were found that were within
5 kcal/mol of the GEM of this analogue. The GEM conformer of this analogue turned
out to be the sixth conformer located by RANDOMSEARCH and its energy was 0.53
kcal/mol. The "state" of a conformer selected for superposition alludes to its relationship
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to the GEM of the particular analogue, in terms of increasing relative energy: GEM <
GEM+l < GEM+2, and so on. This alignment is displayed in Figure 3.9 and was used
for all subsequent experiments in the first CoMFA study.
Figure 3.8 Alignment of All GEM	 Figure 3.9 Alignment #1
Structures
For each of the other four CoMFA studies, the template MP conformer was used
to construct (using SYBYL's Build/Edit option) all other analogues by adding
substituents at the right position on the phenyl ring. Since the template structure was kept
unchanged during construction of the other analogues, and since no energy minimizations
were performed on the constructed structures (see notes in Appendix B), the process
produced automatic alignments for each of these four CoMFA studies. These alignments
(Alignments #2, #3, #4, and #5 for the corresponding CoMFA Studies II — V) are shown
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in Figures 3.10 — 3.13. After these preparatory steps, the CoMFA procedure described in
Chapter 2 was carried out on the 30 MP analogues.
Figure 3.10 Alignment #2	 Figure 3.11 Alignment #3
Figure 3.12 Alignment #4	 Figure 3.13 Alignment #5
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The results of a CoMFA run include residual values, defined as the (Actual —
Predicted) value of (-log IC50), for each analogue. As discussed in Chapter 4, if
warranted by the quality of the experimental data, the predictability of the CoMFA model
can be improved (i.e. the q 2 can be raised) by deleting from the analysis compounds with
large residuals. Chapter 4 also describes the sensitivity of the CoMFA models to various
run-time parameters such as the region box, grid spacing, steric and electrostatic energy
cutoff values, and the column filtering (a) value. The CoMFA region box is the 3D
space surrounding the alignment of molecules and contains lattice points at which the
steric and electrostatic fields are calculated using a probe atom, such as a sp a carbon atom
with +1 charge. Grid spacing is the distance between two lattice points and is 2.00 A by
default. During the calculation of field energies at the lattice points, some values may
exceed the selected cutoffs for the steric and electrostatic energy. These are replaced by
the chosen energy cutoff values, thus making a plateau of the steric fields close to the
center of any atom. The column filtering value, a, is the minimum level of energy




The CoMFA experiments in the studies presented here use the (published 61,67 and
unpublished) nanomolar binding and uptake IC5 0 values for MP analogues of Schweri
and coworkers. The PLS analyses were performed using the [-log (molar IC50)] values.
Five CoMFA studies (1-V) were carried out. CoMFA Study I used the 5 kcal/mol cutoff
GEM conformer as the template for the alignment rule. CoMFA Studies II-V used
conformer numbers 1, 3, 17, and 20, obtained after cluster analysis of the 20 kcal/mol
cutoff data set, as the templates for the respective alignment rules.
4.1 CoMFA Study I
Three sets of experiments were carried out: a) separate CoMFA runs using binding and
uptake data with default grid size and spacing; b) changing the grid spacing and CoMFA
region box size; and c) changing the steric and electrostatic (ES) cutoffs and the column
filtering (o) parameter.
4.1.1 CoMFA Using Default Grid Size and Spacing
Table 4.1 shows the automatically generated default specifications for the CoMFA region
box for the particular alignment used in this study. The x, y, and z coordinates are given
in Angstroms. Automatically-generated region boxes extend by an extra 2 A in all
directions around the aligned structures, thus effectively covering the entire alignment
with sufficient spatial margin. The steric and ES field points were calculated at each of
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the grid points of each of the analogues using the default 2 A grid spacing. The Leave-
One-Out cross-validation method was used to calculate q2, advancing through all 30
analogues and leaving one analogue at a time out of the calculation to predict its (-log
IC 50) value. The optimum number of components was then used to carry out a non-
validated CoMFA run. The results are summarized in Table 4.2 for both cross-validated
and non-validated runs. In the table, "both" refers to inclusion of both steric and ES
fields in the calculations. These CoMFA runs produced barely significant q 2 values of
about 0.5 using binding or uptake data for all 30 analogues (Runs I and 3 in Table 4.2),
indicating an acceptable model. The optimum number of components for both runs was
four and the non-validated r2 was about 0.8-0.9. A comparison of the steric and
electrostatic contributions (about 80% and 20% respectively) for the two runs points to a
preponderance of steric influences. The similarity of the results obtained for binding and
uptake models is probably a consequence of the fact that the binding and uptake data are
highly correlated. 61
Table 4.1 Default Region Box
Table 4.2 Selected CoMFA Results for Binding and Uptake Data
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Runs 2 and 4 were made with only 28 and 29 analogues, respectively. In Run 2,
4-CF3 and 2-OCH3 were dropped; in Run 4, 4-CF3 was dropped due to high predictive
errors (see discussion below and Table 4.3). Run 2 gave the best q 2 (0.590) and
associated r2 (0.934). Runs 5-8 test the use of steric fields only in modeling the binding
and uptake data (Runs 5 and 7) versus only ES fields (Runs 6 and 8) for all 30 analogues.
Since Runs 1 and 3 showed that steric effects contribute about 80% to the binding and
uptake data, it is not surprising that Runs 6 and 8, based on ES fields only, show very
poor values of q2 (around 0.3). Similarly, Runs 5 and 7, based on steric fields alone, give
q2 values close to Runs 1 and 3, which are based on both steric and ES fields. Non-
validated runs were not performed for Runs 5-8 due to low value of q2.
Table 4.3 Actual Binding and Uptake Data and CoMFA Residuals
Actual Data * Binding Residuals -1 	 Uptake Residuals Binding Residuals Uptake Residuals
Binding Uptake With all 30 analogues Without 4-CF3, 2-OCH3 Without 4-CF3

















1 MP 83.0 7.081 224.0 6.650 -0.103 0.045 0.099 0.087 -0.035 0.105 0.174 0.199
2 2-Br 1865.0 5.729 3410.0 5.467 0.860 0.436 0.597 0.339 0.638 0.490 0.609 0.461
3 2-Cl 1946.7 5.711 2660.0 5.575 0.519 0.221 0.709 0.323 0.380 0.167 0.703 0.261
4 2-F 1415.0 5.849 2900.0 5.538 -0.457 -0.399 -0.624 -0.379 -0.283 -0.097 -0.408 -0.113
5 2-naphthyl 11.0 7.959 53.0 7.276 0.578 -0.034 -0.562 -0.087 0.383 0.254 -0.107 0.161
6 2-OCH3 100666.7 3.997 81000.0 4.092 -1.789 0.208 -1.609 0.204 -1.738 -0.157
7 2-OH 23050.0 4.637 35750.0 4.447 -1.065 -0.779 -1.151 -0.757 -1.094 -0.420 -1.239 -0.420
8 3-Br 4.2 8.377 12.8 7.893 0.466 0.455 0.622 0.489 0.532 0.431 0.516 0.411
9 3-C1- 3 21.4 7.670 100.0 7.000 0.014 0.062 -0.888 -0.006 -0.580 -0.024 -0.675 -0.063
10 3-C1 5.1 8.292 23.0 7.638 0.837 0.489 0.655 0.322 0.516 0.318 0.258 0.151
11 3-F 40.5 7.392 160.0 6.796 -0.177 0.110 -0.397 0.041 -0.384 -0.173 -0.376 -0.187
12 3-NH2 265.0 6.577 577.5 6.238 -0.805 -0.177 -0.089 -0.142 0.320 0.026 0.918 0.026
13 3-OCH3 287.5 6.541 635.0 6.197 -0.378 -0.244 0.764 -0.124 0.764 0.172 0.678 0.228
14 3-OH 321.0 6.493 790.0 6.102 -1.548 -0.979 -1.632 -0.904 -1.374 -0.805 -1.296 -0.653
15 3,4-C1 5.3 8.276 7.0 8.155 -0.136 -0.219 0.498 0.105 0.062 -0.148 0.414 0.052
16 3,4-OCH3 810.0 6.092 1760.0 5.754 -L082 -0.265 0.080 -0.221 -1.115 0.110 -0.553 -0.027
17 3,5-CH3 4685 5.329 3041.5 5.517 -1.051 0.005 -0.589 0.208 -1.297 -0.074 -0.918 0.001
18 3,5-C1 65.6 7.183 113.0 6.947 0.378 0.163 0.021 0.108 0.288 0.158 0.149 0.045
19 4-Br 6.9 8.161 26.3 7.580 0.314 0.324 0.090 0.301 0.355 0.118 0.341 0.075
20 4-C2H5 736.7 6.133 1580.0 5.801 -0.098 0.073 -0.527 0.044 -0.224 0.017 -0.210 -0.027
21 4-CF3 615.0 6.211 2365.0 5.626 -2.053 -0.973 -2.201 -0.974
22 4-C143 33.0 7.481 125.5 6.901 0.950 0A81 0.698 0.395 1.024 0.240 0.987 0.179
23 4-Cl 20.6 7.686 73.8 7.132 -0.334 -0.150 -0.652 -0.187 -0.174 -0.271 -0.418 -0.313
24 4-F 35.0 7.456 142.0 6.848 0.514 0.391 0.509 0.277 0.138 0.279 0.092 0.209
25 4-1 14.0 7.854 64.5 7.190 0.428 0.240 0.378 0.164 -0.500 -0.244 -0.457 -0.268
26 4-NH2 34.5 7.462 114.5 6.941 -0.121 0.290 -1.744 0.266 -1.708 -0.136 -1.661 -0.168
27 4-NO2 493.8 6.306 1610.5 5.793 -0.012 -0.115 1.127 -0.076 0.352 -0.122 0.454 0.054
28 4-OCH3 83.0 7.081 292.5 6.534 0.959 0.225 0.930 0.113 0.503 -0.180 0.365 -0.085
29 4-OH 98.0 7.009 340.0 6.468 -0.261 -0.001 -0.227 -0.074 0.003 -0.015 0.026 0.018
30 4-t-butyl 13450.0 4.871 9350.0 5.029 -0.906 0.118 0.137 0.145 -1.386 -0.174 -1.045 -0.048
* The ICcn values are shown in nM units and the -Ina ICsn values are based on molar ICso values. 61,67
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Table 4.3 provides the observed binding and uptake data 61,67 for the 30 MP
analogues, along with the values of (-log IC50) that were used as the biological activity
measurement in the CoMFA analyses. It also lists the residuals, calculated as (Actual —
Predicted) value of (-log IC50), generated in these runs. For the binding run (Run 1 in
Table 4.2), the analogues with the largest (cross-validated) residuals are: 4-CF 3 (-2.053),
2-OCH3 (-1.789), and 3-OH (-1.548). For the uptake run (Run 2 in Table 4.2), the
analogues with the largest (cross-validated) residuals are 4-CF 3 (-2.201), 2-OCH3
(-1.609), 3-OH (-1.632), and 4-NH 2 (-1.744). Since the (cross-validated) q 2 is a better
indicator of the usefulness of the model than the (non-validated) r 2 , one way to improve
q` is to delete those analogues that are poorly predicted. For this reason, a binding
CoMFA run without 4-CF 3 and 2-OCH3 , and an uptake CoMFA run without 4-CF3 were
performed. These results also are shown in Tables 4.2 (Runs 2 and 4) and 4.3 with the
blank spaces in Table 4.3 indicating the analogue that was left out. The q 2 value for the
binding run (Run 2) increased somewhat to about 0.6 without 4-CF3 and 2-OCH 3 , but that
for the uptake run (Run 4) decreased slightly to about 0.4 without 4-CF 3 . However, the
standard error of estimate decreased for these two runs, while the non-validated r2
improved to over 0.9. The steric contribution was again favored over the electrostatic
contribution. However, some large residuals still remain in the 28- and 29-analogue runs.
For the binding run, Run 2, deleting 4-CF 3 and 2-OCH 3 diminished the (cross-validated)
residual for 3-OH (from -1.548 to -1.374), but actually increased it for 4-NH2 (from
-0.121 to -1.744), 3,5-CH3 (from -1.051 to -1.297), and 4-t-butyl (from -0.906 to -1.386).
Similarly, deleting 4-CF3 from the uptake run, Run 4, decreased the (cross-validated)
residuals for 3-OH (from -1.632 to -1.296) and 4-NH2 (from -1.744 to -1.661), but
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increased those for 2-OCH 3 (from -1.609 to -1.738) and 2-OH (from -1.151 to -1.239).
Since deleting analogues with large residuals from subsequent CoMFA runs did not
necessarily improve the predictive power of those runs, and since there is no reason that
the experimental data for those analogues with large residuals would be in error, this
procedure was not continued in CoMFA Studies II — V.
The CoMFA steric and electrostatic coefficient contour maps based on the above
PLS analyses are provided as 3D plots in Plate 2 in Appendix D. The contours were
generated with the following settings: green 80, yellow 35, blue 95, and red 20. For
clarity, only one structure, that of the 2-OCH3 analogue, is depicted in the plots. These
coefficient contour plots may help to identify important regions where any change in the
steric and/or electrostatic fields may affect the bioactivity. It can be seen that there is no
substantive difference between the plots based on binding versus uptake data, nor
between the plots for studies based on different number of analogues.
The plots are interpreted as follows. The steric contours are indicated by the
green and yellow polyhedra while the electrostatic contours are represented by the blue
and red polyhedra. The green steric contours indicate that increasing the bulk in those
areas may help to increase the binding or uptake activity of the MP analogues. The
yellow regions correspond to steric contours which indicate that increasing bulk in those
areas may decrease bioactivity. As shown in the plots, there is a large yellow region just
off the 2-position of the aromatic ring indicating that increasing bulk in this region may
lead to lowering of activity. This is most clearly shown for the displayed 2-OCH 3
analogue which penetrates directly into this disallowed yellow region and has the highest
IC50 value (about 105 nM) among all 30 analogues studied. Other 2-position analogues
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also have very high IC 50 values: 2-Br (1,865 nM), 2-C1 (1,947 nM), 2-F (1,415 nM), and
2-OH (23,050 nM). For the electrostatic coefficient contours, more negative charge in
the red regions may increase bioactivity, while more negative charge in the blue regions
may decrease it. In this way, the color-coded plots are a useful tool for relating the steric
and electrostatic features of the analogues to their biological activity.
4.1.1.1 Predicting Bioactivity of "Novel" Compounds: The whole exercise of
CoMFA is undertaken to generate a useful model that can accurately predict the
bioactivity of a yet-to-be-synthesized compound. For this purpose, the non-validated
CoMFA run with 30 analogues using binding data, both steric and ES fields, default
region box, and the GEM superposition (Run 1 in Table 4.2), was tested by predicting the
bioactivity of some "novel" compounds that were generated by editing a suitable
analogue already aligned on the template. For example, the 2-I structure was made by
replacing the chlorine atom of the 2-C1 analogue in the alignment with an iodine atom on
screen. The predictions were made using the "Predict Property" option in SYBYL.
Table 4.4 gives the predicted (-log IC50) values and the corresponding nanomolar 1050
values for these compounds.
Table 4.4 Predicted Bioactivity of "Novel" Compounds
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To test the robustness of the model the predicted IC50 values of these "novel"
compounds can be evaluated based on the known activity trends of the 30 analogues from
Table 4.3. For example, the relatively inactive 2-position analogues have high IC50
values and, as noted above, stick out into the sterically unfavorable yellow region in the
contour map. The chimeric 2-I analogue is the bulkiest of all the halogen substituted
analogues and it is reasonable that it would have the highest IC 50 value amongst them.
The model predicts an 10 50 of 31,390 nM for 2-1, which is much higher than the IC50
values of all 2-position halogens and comparable to that of the 2-OH analogue (23,050
nM). Similarly, the chimeric 3-1 analogue (25.4 nM) is predicted to have an 1050 value
comparable to 3-CH 3 (21.4 nM) and higher than both 3-Br (4.2 nM) and 3-C1 (5.1 nM).
The brominated MP analogues consistently have a better activity than do the chlorinated
ones: 2-Br (1,865 nM) vs. 2-Cl (1,947 nM), 3-Br (4.2 nM) vs. 3-C1 (5.1 nM), and 4-Br
(6.9 nM) vs. 4-C1 (20.6 nM). In keeping with this trend, the 3,4-Br compound (3.1 nM)
is predicted to have a lower IC50 value than the 3,4-C1 analogue (5.3 nM). Indeed, the
3,4-Br compound may be a good choice to synthesize and provide experimental
verification of the model. It has been suggested to Howard Deutsch, Georgia Institute of
Technology, as a potential synthetic target. The preceding line of reasoning, however,
fails when comparing 3,5-Br (predicted 187 nM) with 3,5-C1 (actual 65.6 nM). No clear
correlations can be made for the remaining "novel" compounds except that the order of
activity for 3,4,5-Br, 3,4,5-C1, and 4,5-C1 appears to be correct.
4.1.1.2 Predicting Bioactivity of "Test Set": A standard procedure to test the
robustness of the model is to divide the analogues into a training set and a test set, derive
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a model based on the training set, and use it to predict the biological activity of the test
set. The test set usually contains about 10% of the compounds and is chosen to reflect a
wide range of bioactivity. An initial test set was created that consisted of six analogues
(20 percent of the total number of analogues studied): 2-Br (1,865 nM), 2-0CH3 (10 5
nM), 3-CH3 (21.4 nM), 3,5-C1 (65.6 nM), 4-Br (6.9 nM), and 4-NO 2 (493.8 nM). This
CoMFA run was carried out using the binding data, both steric and ES field calculations,
the Leave-One-Out cross-validation method, and the default region box (Table 4.1). The
cross-validated and non-validated CoMFA results are summarized in Table 4.5 as Test
1A. The actual and predicted (-log IC 50) values for the compounds of the test set, along
with the corresponding residuals, are provided in Table 4.6 under the column heading
"Test Set 1". A second CoMFA run was performed as above but using a user-defined
CoMFA region box (see Table 4.16 below). The results of this run are listed in Table 4.5
as Test 1B and in Table 4.7 under the column heading "Test Set 1". Since the q2 values
of both these runs were much less than 0.5 {0.289 for the default region box and 0.293 for
the user-defined region box) and therefore not significant, a second test set was created
consisting of three analogues (10 percent of the total number of analogues studied). Two
more CoMFA runs predicting the (-log IC5 0) values of the compounds in the second test
set were carried out using the default or user-defined region box. These runs are listed in
Table 4.5 as Tests 2A and 2B and in Tables 4.6 and 4.7 under the column heading "Test
Set 2". Though Test Set 2 produced improved q 2 values over those produced by Test Set
1, they were still below the 0.5 significance level (0.365 using the default region box and
0.408 using the user-defined region box). These results indicate that the present CoMFA
model based on both steric and ES fields, default region box, and Alignment #1 (Figure
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3.9) may not be the best predictive model. Therefore alterations in the box region and the
grid spacing were made, as described below.
Table 4.5 CoMFA Using Two Training Sets with Two Different Region Boxes
- 'able 4.1; - Fable 4.16
Table 4.6 Bioactivity Predictions of Test Sets Using Default CoMFA Region Box
Table 4.7 Bioactivity Predictions of Test Sets Using User-Defined CoMFA Region Box
47
4.1.2 Resizing CoMFA Region Box and Grid Spacing
Cross-validated CoMFA runs were carried out after altering the size of the CoMFA
region box surrounding the 30 aligned structures and changing the distance between
lattice points in the x, y, and z directions. The binding data and both steric and
electrostatic field calculations were used for these analyses. Three sets of three (for a
total of nine) CoMFA runs were performed as shown in Table 4.8. Three grid spacings
were used at 1.00 A, 1.50 A, and 2.00 A. For each grid spacing, three sizes of the CoMFA
region box were used: "base", "base + 2 A", and "base — 2 A". The "base" size signifies
the minimum whole number end-coordinates beyond the coordinates of the automatically
generated default CoMFA region box (Table 4.1) that would ensure an exact "fit" for the
number of steps with a particular grid spacing. For example, in Table 4.10, the selection
of the low and high x-coordinates as -9.0 and 11.0 respectively ensures that the 1.00 A
grid spacing will cover the x-axis in exactly 21 steps. Addition or subtraction of 2 A
to/from the low and high coordinates of the CoMFA region box yields the "base + 2 A" or
the "base — 2 A" region boxes. The results are summarized in Table 4.8 while the
residuals are listed in Table 4.9. The nine region boxes generated are shown in Tables
4.10 through 4.18.
Resizing of the region box for a given set of CoMFA runs (i.e., at a given grid
spacing) produced virtually no change in the cross-validated q2 of each run of the set.
For example, for the 1.00 A grid spacing, the "base", "base + 2 A", and "base — 2 A"
region boxes, all gave a q2 value of 0.57. Upon varying the grid spacing, however, a
minor change in q2 was effected, with the 1.00 A grid spacing producing the highest q 2 .
Nevertheless, the overall change for the 1.00 A, 1.50 A, and 2.00 A grid spacings is barely
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significant. Consequently, it can be surmised that changing the grid spacing for this
particular alignment had negligible effect on the predictability of the models.
It can be seen from Table 4.8 that the q 2 values for the 1.50 A grid spacing were
the lowest at 0.43, while those for the 1.00 A and 2.00 A were similar at 0.57 and 0.55
respectively. Perhaps this is because the center of the CoMFA region box for the 1.50 A
grid spacing (at 1.5, 2.5, 0.0, see Table 4.13) is different from that for the 1.00 A and 2.00
A grid spacings (at 1.0, 2.0, 0.0, see Table 4.10). Not enough data is available to
corroborate this finding.
Since changing the box region and grid spacing had essentially no effect on the
predictive quality of the CoMFA model, the default values for these were used in the
remaining CoMFA studies in this section, as well as for CoMFA studies II — V.
Table 4.8 Cross-Validated CoMFA Results of Region Box and Grid Spacing Resizing
Table 4.9 Binding Residuals upon Changing Grid Spacing and Region-Box Size
A. CoMFA region boxes for 1.00 A grid spacing
Table 4.10 Base for 1,00 A Grid Spacing
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Table 4.11 Base + 2 A for 1.00 A Grid Spacing
Table 4.12 Base — 2 A for 1.00 A Grid Spacing
B. CoMFA region boxes for 1.50 A grid spacing
Table 4.13 Base for 1.50 A Grid Spacing
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Table 4.14 Base + 1.5 A for 1.50 A Grid Spacing
Table 4.15 Base — 1.5 A for 1.50 A Grid Spacing
C. CoMFA region boxes for 2.00 A grid spacing
Table 4.16 Base for 2.00 A Grid Spacing
52
Table 4.17 Base + 2 A for 2.00 A Grid Spacing
Table 4.18 Base —2 A for 2.00 A Grid Spacing
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4.1.3 Changing Steric and ES Field Cutoffs and a
All previous CoMFA runs were made with both the steric and electrostatic cutoffs set to
30 kcal/mol and a column filtering value of 2. The sensitivity of q2 to variation of these
parameters was tested for the MP analogues, producing the results shown in Table 4.19.
All CoMFA runs in the table were carried out using all 30 analogues, binding data only,
both steric and ES fields, the Leave-One-Out cross-validation method, and the default
CoMFA region box (Table 4.1) and grid spacing (2.0 A). The combinations which result
in the best q2 are highlighted in bold.
Table 4.19 CoMFA Parameter Optimization to Maximize q2 for CoMFA Study I
In kcal/mol "Defaults; Run 1 in Table 4.2
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Changing the steric energy cutoff while keeping the ES energy cutoff at its default
value of 30 kcal/mol increased q2 from 0.477 (for 30/30 Steric/ES energy cutoffs) to
0.555 (for 125/30). Maintaining the steric energy cutoff at 125 kcal/mol while changing
the ES cutoff, further increased the q 2 to 0.573 (for 125/200). Altering the a value next
maximized the q2 to 0.584 (for 125/200 and a = 7). A non-validated CoMFA run was
done on this model producing r 2 = 0.930, standard error of estimate = 0.341, 68.4% steric
contribution, and 31.6% ES contribution. This indicates an increase in r 2 from that
(0.885) produced by using the default energy cutoff and a values. The ES contribution
was significantly increased (from 21.1 %) in agreement with the increased ES energy
cutoff value (from 30 kcal/mol to 200 kcal/mol). The CoMFA steric and electrostatic
coefficient contour map for this model (not shown) was generated with the following
settings: green 80, yellow 35, blue 95, and red 35, and was similar to that generated from
the run using default energy cutoff and a values (Run 1, Table 4.2).
In order to attempt to improve the value of q2 even further, alternative
superposition rules were attempted as described below, in CoMFA studies II — V.
4.2 CoMFA Study II
In this experiment, the MP conformer number 1 from the 20 kcal/mol cutoff data set of
67 random search MP conformers was selected as the template for the alignment for
CoMFA (Alignment #2, see Figure 3.10). CoMFA was done on all 30 analogues using
the binding data only, both steric and ES fields, the Leave-One-Out cross-validation
method, and the default CoMFA region box (Table 4.1) and grid spacing (2.0 A). The
results are given in Table 4.20. CoMFA of all 30 analogues produced a q 2 of 0.466. An
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examination of the residuals for this run indicated that the following analogues had high
(greater than 1.5) values: 2-Naphthyl (7.03), 2-0H (-1.839), 4-OCH 3 (1.782), and 4-C2H5
(1.586). It should be noted here that the 2-Naphthyl analogue does not actually have a
substituent at the 2-position. Rather the second ring of the naphthyl group protrudes into
the region between the 3- and 4- positions. The large residual for 2-Naphthyl seems to
indicate that the data do not predict substituents in this region well. Since the residual
value for 2-Naphthyl was so high, another CoMFA run was done on 29 analogues, with
the 2-Naphthyl omitted. This run raised the q2 value to 0.546. Coupled with the fact that
both runs produced an inadequate r 2 value of less than 0.8, it would seem, therefore, that
these models are unsuitable for predictions of bioactivity and further experiments based
on altering the CoMFA parameters were not pursued.
Table 4.20 Selected Results for CoMFA Study II
Of note, however, is the near-total domination of the steric contributions over the
ES contributions in both the 30-analogue and the 29-analogue CoMFA runs. This
represents a significant increase from the results obtained in CoMFA Study I where the
steric contributions amounted to about 80% and the ES to about 20%. Yet, with a q 2 of
about 0.5, the models in this study as well as those in CoMFA Study I are about the same
in terms of predictability (based on q2).
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4.3 CoMFA Study III
In this study, conformer number 3 from the 67 MP conformers of the 20 kcal/mol data set
was chosen as the template for alignment (Alignment #3, see Figure 3.11). CoMFA was
performed on all 30 analogues using the same parameters as those used in CoMFA Study
II. This run produced a model with a q 2 of 0.459 with optimum number of components at
three. The greatest residual value was -2.099, that of the 4-t-butyl analogue. Other high
residuals were those of 4-CF 3 (-1.405), 3,4-OCH3 (1.409), 4-NO 2 (-1.379), 4-NH2
(1.362), and 2-Naphthyl (1.342). A non-validated run was carried out which gave
standard error of estimate = 0.529, r 2 = 0.809, and steric contribution of 99.3 %. The
results are thus very similar to those obtained in CoMFA Study II and further parameter
variation was not performed.
4.4 CoMFA Study IV
This experiment utilized MP conformer number 17 from the 20 kcal/mol data set for the
template for alignment (Alignment #4, see Figure 3.12). CoMFA was again performed
on all 30 analogues using the parameters as before. A q 2 of 0.531 with optimum number
of components four were obtained. Some analogues with relatively high residuals in this
run were 2-OCH 3 (1.968), 3,5-CH3 (-1.833), 2-Naphthyl (1.618), 4-C2H5 (-1.575), 3-NH2
(-1.574), and 3,5-CI (1.519). The non-validated run produced standard error of estimate
of 0.530, r2 of 0.816, and steric contribution of 98.1%. Thus, a relatively high (cross-
validated) q2 value did not generate a high r2 value. Consequently, this model can also be
deemed inadequate for prediction purposes.
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Since the q2 value in this study was relatively high (0.531), several different
combinations of the steric and ES energy cutoffs were tried with the 30 analogues to
optimize the q2 . The column filtering value, a, was kept at the default 2.0 kcal/mol. The
results are shown in Table 4.21. Upon changing the steric energy cutoff from 30 to 60
kcal/mol, the q2 dropped sharply to 0.360 and further to 0.310 for cutoff values 100
kcal/mol and above. This meant that the steric cutoff of 30 kcal/mol was already at an
optimal level for this model. Raising the ES cutoff values, with the steric cutoff at 30
kcal/mol, did not affect the original q2 of 0.531. This result is in accord with the non-
validated CoMFA run indication of only 1.9% ES contribution for this model.
Table 4.21 Parameter Optimization for CoMFA Study IV
a In kcal/mol °Defaults
4.5 CoMFA Study V
The final CoMFA experiment had MP conformation number 20 from the 20 kcal/mol
RANDOMSEARCH data set as the template for alignment (Alignment #5, see Figure 3.13).
CoMFA was carried out on all 30 analogues using the binding data only, both steric and
ES fields, the Leave-One-Out cross-validation method, and other defaults: default
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CoMFA region box (Table 4.1), grid spacing (2.0 A), steric and ES energy cutoffs (both
30 kcal/mol), and a (2 kcal/mol). This run produced the best (cross-validated) q2 (0.662)
obtained so far using the initial parameters listed above. The optimum number of
components for this run was four. Only three analogues had residuals larger than 1.5:
2-Naphthyl (-1.587), 4-t-butyl (1.897), and 2-OCH 3 (-2.569). The non-validated CoMFA
run gave r2 = 0.901, standard error of estimate = 0.388, and steric contributions = 98.2%.
A CoMFA coefficient contour map (not shown) was generated for this model (with green
80, yellow 35, blue 90, and red 80). As before, a sterically unfavorable yellow region
was present off the 2-position (which correlates with the inactivity of the 2-position
analogues) and between the 4- and 5-positions (which correlates with the inactivity of the
4-t-butyl analogue).
4.5.1 Changing Steric and ES Field Cutoffs and a
Since a good initial q2 was obtained above, and since optimization of some CoMFA
parameters in CoMFA Study I did lead to an increase in q 2 , several runs were conducted
using various steric and electrostatic energy cutoffs and a values. The results are given
in Table 4.22. Increasing the steric energy cutoff to 40 kcaUmol (keeping the ES energy
cutoff at the default 30 kcal/mol) decreased the q 2 to 0.632. Further increase in the steric
cutoff resulted in progressive decrease in q 2 . Increasing the ES cutoff (keeping the steric
cutoff at 30 kcal/mol) decreased the q 2 to 0.557, which increased marginally upon further
increasing ES cutoff but which remained well below the original 0.662 value.
As Table 4.22 shows, altering the a value (at the default steric and ES energy
cutoffs since these gave the highest q 2) mostly led to small differences in q 2, as in
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CoMFA study I. However, for 6 = 9, the q2 shot up to 0.765, clearly giving the best (12
value obtained in any of the studies described here. The optimum number of components
for this model, however, was 11, indicating a very complex model. A non-validated
CoMFA run was carried out on this model giving a high r 2 of 0.972, a relatively low
standard error of estimate of 0.242, and a steric contribution of 96.3%. The CoMFA
coefficients contour map generated for this model (Plate 3, Appendix D) was essentially
the same as the one produced by the 0.662 q2 model (not shown) indicating that alteration
of o does not affect the map for this model. In addition, the qualitative information
obtained from this map is the same as that obtained from the maps in CoMFA Study I;
both indicate sterically unfavorable yellow regions corresponding to the inactive 2-OCH3
and 4-t-butyl analogues.
Table 4.22 Parameter Optimization for CoMFA Study V
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4.5.2 Predicting Bioactivity of "Test Set"
The predictability of a CoMFA model based on Alignment #5 was compared to that of
the CoMFA model based on Alignment #1 of CoMFA Study I using the same test and
training sets as in Study I (see Section 4.1.1.2). The steric and ES energy cutoffs and the
a value used were those that maximized q 2 to 0.765, i.e. 30/30 kcal/mol and 9
respectively. CoMFA was carried out using the binding only data, both steric and ES
fields, the Leave-One-Out cross-validation method, and the default region box (Table
4.1). The cross-validated and non-validated CoMFA results are given as Test 1 (for the
20% Test Set 1) and as Test 2 (for the 10% Test Set 2) in Table 4.23. Table 4.24 lists the
residuals for the compounds in Test Set 1 under the column heading "Test Set 1" and
those for the compounds in Test Set 2 under the column heading "Test Set 2".
Table 4.23 CoMFA Using Two Training Sets for CoMFA Study V
Table 4. 1
Table 4.24 Bioactivity Predictions of Test Sets for CoMFA Study V
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Test 1 produced a low q 2 of 0.279 with optimum number of components being
four. The non-validated CoMFA run for this model, however, gave a high r 2 value of
0.922. This may explain the marginally better predictability of this model over its
counterpart in CoMFA Study I (i.e. Test 1A in Table 4.5) which had a slightly higher q2
of 0.289 but a lower r2 of 0.859. In Table 4.24, two compounds in Test Set 1 (3-CH3 and
3,5-C1) came within a hundredth of their actual (-log IC50) values as against only one
(3-CH 3) in Test Set 1A (Table 4.5). Test 2 had a high q2 value of 0.746 as well as a high
r2 value of 0.947 (both higher than their counterparts for Test Set 2A in CoMFA Study I,
Table 4.5 with q2 of 0.365 and r2 of 0.860). CoMFA Study I gave about the same results
whether the test set consisted of 10 or 20% of the analogues. CoMFA Study V gave
much better results for the smaller training set and seems to be a reasonably predictive
model.
4.5.3 Predicting Bioactivity of "Novel" Compounds
The CoMFA model with q2 = 0.765 was used to predict the activity of the same "novel"
compounds as CoMFA Study I. The predicted (-log IC50) values and the corresponding
nanomolar IC50 values for these compounds are listed in Table 4.25. Most of the
compounds were predicted to have a lower IC50 value than those predicted in CoMFA
Study I. By and large, the pattern remained the same with 2-I being predicted to have a
high IC50 of 2630 nM and 3,4-Br being predicted to have an even lower (than in CoMFA
Study I where it was 3.1 nM) IC50 of 0.9 nM. The ultimate test of the predictability of the
models will be the synthesis and testing of some of these analogues by the Deutsch and
Schweri groups.




Several conclusions can be drawn from the CoMFA studies carried out on the MP
analogues in this research. CoMFA results that were based on the binding data were
similar to those based on the uptake data reflecting the highly correlated nature of the two
sets of data. Changing the grid spacing and region box parameters did not significantly
affect q2 . Changing the steric and ES energy cutoff and column filtering (a) values had a
much larger effect on q 2 , though varying the a value alone usually produced a smaller
change in q2 . Changing the template structure (i.e. the hypothesized bioactive
conformation) for superposition produced the biggest effect in q2 , underlining the
importance of using a thoroughly investigated alignment rule for useful CoMFA results.
Thus, in order of decreasing effect on q 2 are: the template structure > energy cutoff value
> a value > grid spacing and region box parameters. In addition, the steric and ES
energy cutoffs can affect the steric and ES contributions in the non-validated runs. The
non-validated runs indicated the dominance of steric effects in all the analyses.
The best (cross-validated) q2 for the GEM conformation of MP (conformer
number 6 from the 5 kcal/mol data set or conformer number 14 from the 20 kcal/mol data
set) was 0.584 and was obtained using the default region box, steric/ES cutoffs of
125/200 kcal/mol, and a a value of 7. The (non-validated) r2 for this model was 0.930,
while the steric and ES contributions were 68.4% and 31.6% respectively.
The best overall (cross-validated) q2 was 0.765 and was achieved using the MP
conformer number 20 from the 20 kcal/mol data set, the default region box, and the
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default steric and ES cutoffs (30/30 kcal/mol), but with a a value of 9. The (non-
validated) r2 for this model was 0.972, while the steric and ES contributions were 96.3%
and 3.7% respectively. Thus, by q 2 and r2 , MP conformer number 20 produced a better
model than did the MP GEM conformer.
By predictability of test sets, CoMFA based on MP conformer number 20 was
slightly better than that based on the MP GEM conformer for the 20 percent test set but
about the same for the 10 percent test set.
The CoMFA coefficients contour maps generated for the two models, i.e., those
based either on the MP conformer 20 or on the MP GEM conformer, produced
qualitatively similar results even though the q2 were different (0.765 vs. 0.584). In both
maps, the sterically unfavorable yellow regions around the 2- and the 4-position on the
phenyl ring correlated with the poor IC 50 values of the 2-OCH3 (105 nM) and the 4-t-
butyl analogues (13,450 nM). In addition, the 2-position analogues have poor IC 50 values
because they protrude into a sterically unfavorable region.
The model using MP conformer number 20 as the template predicted the "novel"
compounds to be more active than the model that used the MP GEM conformer as the
template. However, the ultimate test of these models will be the synthesis and testing of
these compounds by Drs. Howard Deutsch and Margaret Schweri. A novel compound
for synthesis and testing is 3,4-Br MP.
APPENDIX A
SYBYL PARAMETERS USED FOR RANDOMSEARCH
(Eliminated piperidine ring inversion)
APPENDIX B
NOTES ON METHODOLOGY
A. The ninety-eight 2D neutral methylphenidates (of which 30 were studied in this
research) of Howard Deutsch were provided by him as a ".sdf' file and were
optimized using SYBYL to give rise to their 3D structures.
B. This collection of compounds consisted of mostly threo (R,R or S,S configuration of
the two chiral carbons in the analogs) and some erythro (R,S configuration)
structures. Since SYBYL assigned random configurations during minimization of the
2D structures, all the threo structures were modified, wherever necessary, to have the
(R,R) configuration.
C. The ninety-eight analogues were divided into seven general "classes" and the DISCO
features assigned to each threo analogue were also identified and recorded.
Conformational analysis was performed using RANDOMSEARCH on the 30 threo
structures belonging to class "A." This class was selected because it had the largest
number of analogues to work with.
D. Each analogue was submitted for random search with its piperidine ring as an
"aggregate".
E. During the course of this study, it was noted that the analogues used in the early, trial
computations had been assigned by SYBYL the wrong carbon atom-type in the
aromatic ring. This was due to a probable bug in the software that didn't recognize
the correct carbon atom-type while reading the molecules from the original ".sdf' file
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F. that contained them. Subsequently, the analogues were modified to have the correct
carbon atom-type and then subjected to RANDOMSEARCH again.
G. The superpositions of the MP analogues that produced the five alignments considered
in this study were carried out in SYBYL using the "Align Database" option. This
option aligns all molecules present in a database and that contain the indicated
substructure, with the selected template molecule by minimizing the RMS distance to
the substructure atoms in that template molecule.
H. For CoMFA Studies II — V, systematic search was performed on the analogues
containing substituents with one or more rotatable bonds and on the 2-Naphthyl
analogue. This was done to account for the rotations around such bonds in these
analogues and the least energetic conformer was selected for the superposition.
Details
A. Conversion of the ninety-eight 2D neutral methylphenidates to their 3D structures: 
The "sdf' file sent by Howard Deutsch, hdtestl .sdf, contained 2D structures of
ninety-eight methyiphenidate analogues. This file was opened in SYBYL as a
molecular spreadsheet (MSS) and each row was treated as follows:
a) Highlight the row.
b) MSS >> File >> Put rows into molecular areas.
c) Compute >> Minimize. The defaults were used during minimization.
d) Build/Edit >> Name molecule.
e) Save as... [molecule name]
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The molecules were saved in a database (compounds.mdb) and this was used as the
data source for a spreadsheet (compounds.tbl). The IC 50 values for WIN binding and
uptake and other values included by Howard Deutsch were entered in this
spreadsheet.
B. Conversion of all threo structures to their (R, R) configuration: 
a) Find chirality:
I. Build/Edit >> Other tools >> Find Chirality
2. Choose RS
3. Choose All (The chirality for all chiral centers will be listed in the console
window)
b) Change chirality:
I. Build/Edit >> Other tools >> Invert
2. Click on the desired individual atom(s)
3. Compute >> Minimize
The (R, R) threo compounds were saved in a new database (threos.mdb) and this was
used as the data source for a new spreadsheet (threos.tbl).
D. Consistency was maintained in the following conditions:
a) All structures submitted for random search had the (R, R) configuration.
b) The piperidine ring was in the chair form.
c) The bulky group attached to the piperidine ring and also the hydrogen on the
nitrogen in the piperidine ring were both in the equatorial position. (The
Build/Edit >> Sketch molecule >> Move atom command was used, where
necessary, to get the equatorial position.)
d) To maintain the above consistency, the piperidine ring of each analogue was
submitted as an active aggregate (see below for procedure). This was done so that
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during random search this ring may remain rigid to avoid ring inversion. This
would enable RANDOMSEARCH to search through 10,000 cycles using only the
conformations that have the bulky group in the equatorial position and not in the
more energetic axial position.
To define an aggregate:
1. Read the molecule on screen
2. Build/Edit >> Aggregates
3. Choose New
4. Pick desired atoms and press OK
5. Enter a name for the aggregate and an optional comment string
E. Modification of aromatic carbon atom type:
a) Read analogue on screen
b) Build/Edit >> Modify >> Atom >> Type
c) Pick atom(s) to modify
d) Choose the correct atom type
e) Compute >> Minimize
F. Using the "Align Database" option in SYBYL: Once the database containing the 30
analogues in the hypothesized conformation was created, it was subjected to database
alignment as a final preparatory step before CoMFA. The following steps describe
the SYBYL commands used for this purpose:
a) File >> Align Database...
b) Select the database that contains the structures to be aligned
c) Select the template molecule structure from the structures in the database
d) Select the core substructure of the template that will be used for alignment
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e) Select "Inertial" orientation (inertially aligns the template molecule to get a more
robust CoMFA with a good q2)
f) Select "Existing" database (for storage of aligned molecules)
g) Select "Align all molecules"
G. Systematic search: Systematic search was performed as follows on 2-OCH3, 2-OH,
3-CH3, 3-OCH3, 3-0H, 3,4-OCH3, 3,5-CH3, 4-C 2H5, 4-CF3, 4-CH3 , 4-OCH3 , 4-OH,
4-t-butyl, and 2-Naphthyl.
a) Read a molecule on screen
b) Compute >> Search >> Systematic Search
c) Select bond(s)
d) Select increment size (10° if one bond was selected and 30° if more than one
bonds were selected)
e) Set all van der Waals radius scale factors to zero
f) Select "Compute energy" = On
g) Select "Use electrostatics" = On
h) Select "Write angle file" = On
Upon completion of the search, a database containing the new conformers is created.
Then use Analyze >> Search >> Systematic Search to select the appropriate
conformer.
APPENDIX C
SCATTER GRAPHS FOR TORSIONAL ANGLE ANALYSIS
Sets of scatter plots for conformers of MP and of the 2-, 3, and 4-position Br, Cl, F,
OCH3 , and OH analogues are provided (courtesy: Joseph Hinksmon) in this appendix.
Each set shows, for a particular pair of torsional angles (4)1 vs. 1)2, 1)l vs. 1)3, or 1)2
vs.1)3), four plots: that of MP, and those of the 2-, 3-, and 4-substitutions of an analogue.
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This appendix contains three color figures for which the legend is given below.
Legend:
Plate I Local Energy Minima (2-Position Analogues Vs. MP). The green points signify
the local energy minima of the MP conformers located at the torsional angle values
indicated for the plot. The red points are the local energy minima for all conformers of
all 2-position analogues.
Plate 2 CoMFA Coefficient Contour Plots (Study I, using MP conformer 14 as template).
1A: Map for CoMFA of all 30 analogues using binding data (q 2 = 0.477, r2 = 0.885; see
Table 4.2, Run 1). 1B: Map with 2-OCH 3 and 4-CF3 removed from analysis; also using
binding data (q2 = 0.590, r2 = 0.934; see Table 4.2, Run 2). 2A: Map for CoMFA of all
30 analogues using uptake data (q 2 = 0.494, r2 = 0.865; see Table 4.2, Run 3). 2B: Map
with 4-CF3 removed; using uptake data (q2 = 0.444, r2 = 0.942; see Table 4.2, Run 4).
The contours were generated using green (80), yellow (35), blue (95), and red (20). The
yellow and green regions indicate areas where more steric bulk is unfavorable and
favored respectively, while the blue and red regions indicate areas where more negative
charge may worsen or improve bioactivity respectively.
Plate 3 CoMFA Coefficient Contour Plot (Study V, using MP conformer 20 as template).
Map for CoMFA of all 30 analogues using binding data, steric/ES cutoffs of 30/30
kcal/mol, and a = 9 (q2 = 0.765, r2 = 0.972; see Table 4.22). The contours were
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